| Literature DB >> 31391470 |
Anke Doyon1,2, Pascal Haas3, Sevcan Erdem4,5, Bruno Ranchin6,5, Behrouz Kassai7, Francesca Mencarelli8,5, Francesca Lugani9,5, Jerome Harambat10,5, Maria Chiara Matteucci11,5, Marcello Chinali12,5, Sandra Habbig13,5, Ariane Zaloszyc14,5, Sara Testa15,5, Enrico Vidal16,5, Charlotte Gimpel17,5, Karolis Azukaitis18,5, Alexander Kovacevic19, Uwe Querfeld20,5, Franz Schaefer3,5.
Abstract
Children with chronic kidney disease suffer from excessive cardiovascular mortality and early alterations of the cardiovascular system. Tissue doppler imaging is a validated echocardiographic tool to assess early systolic and diastolic cardiac dysfunction. We hypothesized that tissue Doppler velocities would reveal reduced cardiac function in children with chronic kidney disease compared to healthy children. A standardized echocardiographic exam was performed in 128 patients of the Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) Study aged 6-17 years with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2. Tissue Doppler measurements included early (E') and late (A') diastolic and systolic (S') velocity at the mitral and septal annulus of the left ventricle. Measured values were normalized to z-scores using published reference data. Predictors of E'/A', E/E', S' and left ventricular mass index (LVMI) were assessed by multiple linear regression analyses. Tissue Doppler E' was reduced and tissue Doppler A' increased, resulting in a reduced tissue Doppler E'/A' ratio (z-score -0.14, p < 0.0001) indicating reduced diastolic function compared to healthy children. Reduced tissue Doppler E'/A' Z-Scores were independently associated with lower eGFR (p = 0.002) and increased systolic blood pressure (p = 0.02). While E/E' Z-Scores were increased (Z-score 0.57, p < 0.0001), patients treated with pharmacological RAS blockade but not with other antihypertensive treatments had significantly lower E/E' and higher E'/A' Z-Scores. Systolic tissue Doppler velocities were significantly decreased (Z-score -0.24, p = 0.001) and inversely correlated with E/E' Z-Scores (r = -0.41, p < 0.0001). LVMI was not associated with systolic or diastolic tissue Doppler velocities. Concentric left ventricular hypertrophy showed a tendency to lower S' in multivariate analysis (p = 0.13) but no association to diastolic function. Concentric left ventricular geometry was significantly associated with lower midwall fractional shortening. In summary, systolic and diastolic function assessed by tissue Doppler is impaired. eGFR, systolic blood pressure and the type of antihypertensive medications are significant predictors of diastolic function in children with CKD. Left ventricular morphology is largely independent of tissue Doppler velocities. Tissue Doppler velocities provide sensitive information about early left ventricular dysfunction in this population.Entities:
Mesh:
Year: 2019 PMID: 31391470 PMCID: PMC6685994 DOI: 10.1038/s41598-019-46653-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Subject characteristics in 128 children with CKD. Findings are stratified by CKD stage.
| N | All | CKD 2-3b | CKD 4–5 | Dialysis |
|---|---|---|---|---|
| 128 | 46 | 69 | 13 | |
| Age (years) | 12.7 ± 3.5 | 12.8 ± 3.25 | 12.4 | 14.3 |
| % male | 72.7 | 69.6 | 73.9 | 76.9 |
| BMI z-score | 0.16 ± 1.10 | 0.13 ± 1.22 | 0.19 ± 1.08 | 0.07 ± 0.83 |
| Height z-score | −0.98 ± 1.08 | −0.83 ± 0.91 | −0.96 ± 1.08 | −1.66 ± 1.44 |
| Systolic BP z-score | 0.59 ± 1.14 | 0.46 ± 1.11 | 0.54 ± 1.10 | 1.33 ± 1.26 |
| Diastolic BP z-score | 0.31 ± 0.97 | 0.28 ± 0.83 | 0.3 ± 1.03 | 0.41 ± 1.16 |
| eGFR (ml/min/1.73 m2) | 25.8 ± 11.4 | 38.1 ± 6.83 | 21 ± 4.55 | n.a. |
| Serum albumin (g/L) | 39.9 ± 3.67 | 39.7 ± 3.71 | 40.3 ± 3.47 | 37.6 ± 4.12 |
| Serum hemoglobin (g/dl) | 11.9 ± 1.77 | 12.3 ± 2.3 | 11.8 ± 1.35 | 11.09 ± 1.37 |
| Serum LDL cholesterol (mg/dl) | 106 ± 36 | 105 ± 35 | 110 ± 37 | 85 ± 23 |
| Serum HDL cholesterol (mg/dl) | 53.6 ± 13.8 | 56.4 ± 15.0 | 52.0 ± 13.1 | 51.4 ± 11.6 |
| Serum bicarbonate (mM) | 22.9 ± 3.66 | 23.6 ± 2.78 | 21.9 ± 3.75 | 25.6 ± 4.5 |
| Serum calcium (mM) | 2.35 ± 0.18 | 2.33 ± 0.15 | 2.34 ± 0.20 | 2.46 ± 0.18 |
| Serum phosphate (mM) | 1.53 ± 0.29 | 1.40 ± 0.21 | 1.59 ± 0.31 | 1.69 ± 0.29 |
| Serum iPTH (pmol/l) | 13.7 (19.5) | 11.6 (32.7) | 15.3 (17.1) | 17.0 (18.4) |
| CRP (mg/l) | 0.39 (0.9) | 0.3 (0.91) | 0.37 (0.62) | 0.7 (1.57) |
| Albuminuria (mg/g creatinine) | 288 (849) | 177 (452) | 324 (967) | 618 (1197) |
| 78 (60.9) | 25 (54.3) | 45 (65.2) | 8 (61.5) | |
| RAS Inhibitor | 57 (44.5) | 21 (45.7) | 31 (44.9) | 5 (38.5) |
| Calcium blockers | 25 (19.5) | 6 (13) | 18 (26.1) | 1 (7.7) |
| Diuretics | 9 (7) | 1 (2.2) | 5 (7.3) | 3 (23.1) |
| Other BP medication | 18 (14.1) | 1 (2.2) | 13 (18.8) | 4 (30.8) |
|
| ||||
| RAS Inhibitor monotherapy | 42 (32.8) | 18 (39.1) | 20 (29.0) | 4 (30.8) |
| RAS Inhibitor + other AHT | 15 (11.7) | 3 (6.5) | 11 (15.9) | 1 (7.7) |
| Non-RAS inhibitor monotherapy | 11 (8.6) | 3 (6.5) | 7 (10.1) | 1 (7.7) |
| Non-RAS combination therapy | 10 (7.8) | 1 (2.2) | 7 (10.1) | 2 (15.4) |
|
| ||||
| Vitamin D supplement | 32 (25) | 9 (19.6) | 21 (30.4) | 2 (15.4) |
| Calcitriol | 74 (57.8) | 20 (43.5) | 46 (66.7) | 8 (61.5) |
| Phosphate binders | 54 (42.2) | 11 (23.9) | 30 (43.5) | 13 (100) |
| Erythropoiesis stimulating agent | 54 (42.2) | 12 (26.1) | 31 (44.9) | 11 (84.6) |
Values are Mean ± SD or Median (IQR) as appropriate; eGFR, estimated Glomerular Filtration Rate; BP, Blood Pressure; RAS, Renin Angiotensin System; AHT, Antihypertensive Therapy.
Conventional echocardiographic findings in 128 children with CKD, stratified by CKD stage.
| N | All | CKD 2-3b | CKD 4-5 | Dialysis |
|---|---|---|---|---|
| 128 | 46 | 69 | 13 | |
| LVMI (g/m2.16 + 0.09) | 45.2 ± 10.4 | 41.2 ± 8.15 | 46.5 ± 10.5 | 50.6 ± 13.5 |
| Relative Wall Thickness | 0.43 ± 0.25 | 0.42 ± 0.11 | 0.43 ± 0.13 | 0.49 ± 0.20 |
| LV hypertrophy | 60 (46.9%) | 16 (34.8%) | 35 (50.7%) | 9 (69.2%) |
| Eccentric | 20 (15.6%) | 5 (10.9%) | 22 (20.3%) | 1 (7.7%) |
| Concentric | 40 (31.2%) | 22 (23.9%) | 14 (30.4%) | 8 (61.5%) |
| Concentric LV remodeling | 38 (29.7%) | 16 (34.8%) | 22 (31.9%) | — |
| Endocardial fractional shortening (EFS) | 37.9 ± 7.72 | 39.5 ± 8.19 | 36.3 ± 7.49 | 40.6 ± 5.60 |
| Midwall fractional shortening (MFS) | 16.4 ± 3.58 | 17.3 ± 3.48 | 15.8 ± 3.58 | 15.9 ± 3.54 |
| E | 99.3 ± 16.8 | 98.2 ± 14.6 | 99.4 ± 1.85 | 103.1 ± 17.15 |
| E/A Ratio | 1.89 ± 0.57 | 1.94 ± 0.55 | 1.86 ± 0.61 | 1.87 ± 0.46 |
| IVS diastolic (cm) | 0.90 ± 0.19 | 0.86 ± 0.16 | 0.91 ± 0.18 | 0.96 ± 0.26 |
| LVID diastolic (cm) | 3.95 ± 0.56 | 3.95 ± 0.54 | 3.95 ± 0.57 | 3.99 ± 0.63 |
| PW diastolic (cm) | 0.86 ± 0.19 | 0.84 ± 0.16 | 0.86 ± 0.19 | 0.98 ± 0.25 |
| IVS systolic (cm) | 1.4 ± 1.27 | 1.59 ± 2.06 | 1.26 ± 0.27 | 1.45 ± 0.24 |
LVMI, Left ventricular mass index; E, Early diastolic velocity (cm/s); A, Atrial; E/A ratio Early to atrial diastolic Doppler flow velocity; IVS Interventricular septum (cm); LVID Left ventricular internal diameter (cm); PW Posterior wall (cm).
Tissue Doppler Results in 128 children with CKD, stratified by CKD stage. Tissue Doppler Velocities (Z-Scores, Mean ± SD).
| All | CKD 2-3b | CKD 4-5 | Dialysis | |
|---|---|---|---|---|
|
| ||||
| Mitral anular | −0.24 ± 1.07* | −0.14 ± 1.20 | −0.24 ± 0.99 | −0.62 ± 0.94 |
| Septal | −0.69 ± 1.02*** | −0.60 ± 1.10 | −0.77 ± 1.00 | −0.58 ± 0.88 |
| Combined | −0.45 ± 0.94*** | −0.37 ± 1.05 | −0.48 ± 0.90 | −0.60 ± 0.77 |
|
| ||||
| Mitral anular | 0.21 ± 1.11* | −0.02 ± 0.97B;C | 0.21 ± 1.11A | 1.01 ± 1.35A |
| Septal | 0.22 ± 0.96*** | 0.04 ± 1.02 | 0.33 ± 0.95 | 0.29 ± 0.74 |
| Combined | 0.23 ± 0.95* | 0.01 ± 0.90B | 0.30 ± 0.96A | 0.65 ± 0.89 |
|
| ||||
| Mitral anular | −0.11 ± 1.03 | −0.17 ± 1.05 | −0.10 ± 1.01 | 0.09 ± 1.10 |
| Septal | −0.38 ± 0.93*** | −0.39 ± 0.81 | −0.43 ± 1.03 | −0.09 ± 0.81 |
| Combined | −0.24 ± 0.85* | −0.28 ± 0.84 | −0.26 ± 0.86 | 0.002 ± 0.90 |
|
| ||||
| Mitral anular | −0.08 ± 0.34* | 0.03 ± 0.35C | −0.09 ± 0.31C | −0.40 ± 0.18B |
| Septal | −0.20 ± 0.40*** | −0.10 ± 0.43 | −0.26 ± 0.36 | −0.19 ± 0.40 |
| Combined | −0.14 ± 0.3*** | −0.03 ± 0.34B,C | −0.18 ± 0.28A | −0.29 ± 0.18 A |
|
| ||||
| Mitral anular | 0.34 ± 0.98** | 0.18 ± 0.83 | 0.35 ± 1.01 | 0.82 ± 1.18 |
| Septal | 0.81 ± 1.21*** | 0.63 ± 1.10 | 0.95 ± 1.22 | 0.85 ± 1.54 |
| Combined | 0.57 ± 1.00*** | 0.40 ± 0.89 | 0.64 ± 1.01 | 0.83 ± 1.31 |
*p < 0.05;**p < 0.001;***p < 0.0001 compared to reference population.
A: different from CKD 2-3b; B: different from CKD 4–5; C: different from Dialysis (all p < 0.05).
Figure 1Distribution of left ventricular tissue Doppler measures in 128 children with CKD. Data are expressed as Z-scores. (LVFP = Left ventricular filling pressure, boxes and whiskers: Median, 10th, 25th, 75th and 90th percentiles).
Figure 2Association of left ventricular filling pressure (E/E’) with systolic tissue Doppler Velocity (S’).
Multivariable models of Tissue Doppler velocities, including E’/A’, E/E’ and S’.
| E’/A' | E/E’ | S' | ||||
|---|---|---|---|---|---|---|
| Estimate | P | Estimate | P | Estimate | P | |
| Intercept | −0.28 ± 0.14 | 0.05 | 0.09 ± 0.50 | 0.86 | −0.59 ± 0.39 | 0.14 |
| Age (years) | −0.008 ± 0.008 | 0.27 | 0.04 ± 0.03 | 0.2 | 0.05 ± 0.02 | 0.03 |
| Height Z-score | −0.03 ± 0.03 | 0.35 | −0.26 ± 0.10 | 0.008 | −0.001 ± 0.08 | 0.98 |
| Male sex | 0.57 ± 0.16 | 0.0009 | ||||
| eGFR | 0.008 ± 0.002 | 0.002 | −0.003 ± 0.008 | 0.71 | −0.01 ± 0.006 | 0.07 |
| Systolic BP Z-score | −0.07 ± 0.02 | 0.02 | ||||
| ACEi/ARB therapy | 0.13 ± 0.05 | 0.02 | −0.37 ± 0.19 | 0.05 | ||
| E/E' | −0.05 ± 0.03 | 0.08 | −0.40 ± 0.08 | <0.0001 | ||
| Concentric LV hypertrophy | 0.08 ± 0.06 | 0.18 | −0.25 ± 0.16 | 0.13 | ||
eGFR, estimated Glomerular Filtration rate (ml/min/1.73 m2); ACE, Angiotensine converting enzyme inhibitor; ARB, Angiotensine receptor blockade, E/E’ Early conventional to tissue Doppler diastolic velocity (cm/s); LV, left ventricular.
Multivariable logistic regression model for Concentric LVH and Concentric Remodeling
| Concentric LVH | Concentric Geometry | |||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (years) | 1.22 (1.05, 1.42) | 0.011 | 0.991 (0.85, 1.15) | 0.903 |
| Height Z-score | 0.65 (0.40, 1.07) | 0.090 | 1.441 (0.84, 2.48) | 0.185 |
| Male sex | 4.78 (1.36, 16.79) | 0.015 | 1.37 (0.42, 4.44) | 0.602 |
| eGFR | 1.00 (0.95, 1.04) | 0.826 | 1.035 (0.99, 1.08) | 0.149 |
| Systolic BP Z-score | 1.83 (1.17, 2.86) | 0.008 | 1.61 (1.03, 2.52) | 0.036 |
| MFS | 0.79 (0.68, 0.92) | 0.002 | 0.59 (0.48, 0.73) | <0.0001 |
eGFR, estimated Glomerular Filtration rate (ml/min/1.73 m2; MFS, midwall fractional shortening; LVH, left ventricular hypertrophy.